Inflammation Theme: Biotech & Pharma Sector Surges +9.15% in a Week - $CHRS $AMGN $PFE $JNJ $ATXS $RETA $ANAB $ZYME $ALLK
The inflammation theme is experiencing a remarkable surge in the biotech and pharmaceutical sector, with an impressive gain of +9.15% in just one week. This theme includes a diverse group of companies that are dedicated to the development of groundbreaking treatments for cancer, inflammation, and other diseases related to cell proliferation. Investors are closely watching the market movements in this category as it offers exciting opportunities for both short-term and long-term gains.
For those interested in the inflammation theme within the biotech and pharmaceutical sector, Tickeron's AI robot, "Swing Trader: Deep Trend Analysis v.2 (TA)," offers a remarkable annualized return of +67%. Don't miss the chance to explore potential swings in companies like AMGN, PFE, and JNJ with the AI-powered insights, increasing your chances of capitalizing on profitable opportunities within this theme.
Industry Description:
The inflammation theme focuses on biotech and pharmaceutical companies engaged in pioneering treatments for cancer, inflammation, and other diseases related to cell proliferation. These companies utilize cutting-edge technologies and research to develop therapies that address unmet medical needs. As leaders in the biotech and pharma sector, they contribute significantly to advancements in medical science and healthcare. Some of the notable companies operating in this field include Coherus BioSciences (CHRS), Amgen Inc. (AMGN), Pfizer Inc. (PFE), Johnson & Johnson (JNJ), Anteris Technologies Limited (ATXS), Reata Pharmaceuticals Inc. (RETA), AnaptysBio, Inc. (ANAB), Zymeworks Inc. (ZYME), and Allakos Inc. (ALLK).
Market Cap:
The average market capitalization across the inflammation theme is 64.5B. The market cap for tickers in this group ranges from 13.8M to an impressive 438.9B, with Johnson & Johnson (JNJ) holding the highest valuation at 438.9B and FWP being the lowest valued company at 13.8M.
High and Low Price Notable News:
Over the past week, the inflammation theme demonstrated robust performance, with an average weekly price growth of 7.27%. Notable price movements include a significant 56.95% price growth by RETA and a -4.19% decline in CHRS.
- 7/22/23 6:50 AM: Johnson & Johnson (JNJ, $170.19) was a top weekly gainer, with a +6.46% jump.
- 7/7/23 12:30 AM: Coherus BioSciences (CHRS, $4.64) was a top weekly gainer, with a +10.74% jump. Expect an Uptrend reversal.
- 6/27/23 12:47 AM: Pfizer (PFE, $36.89) was a top loser this week, declining -7.91%.
Volume:
The average weekly volume growth across all stocks in the inflammation theme was -41.89%. While monthly volume growth recorded a slight increase of 0.22%, quarterly volume growth declined by -34.7%.
- 8/1/23 1:27 AM: The volume for Reata Pharmaceuticals stock increased for one day, resulting in a record-breaking daily growth of 224% of the 65-Day Volume Moving Average.
- 6/23/23 11:57 PM: The volume for Zymeworks stock increased for one day, resulting in a record-breaking daily growth of 1,128% of the 65-Day Volume Moving Average.
- 6/23/23 11:57 PM: The volume for AnaptysBio stock increased for one day, resulting in a record-breaking daily growth of 281% of the 65-Day Volume Moving Average.
Fundamental Analysis Ratings:
The average fundamental analysis ratings for the inflammation theme, on a scale from 1 (best) to 100 (worst), are as follows:
- Valuation Rating: 44
- P/E Growth Rating: 84
- Price Growth Rating: 55
- SMR Rating: 74
- Profit Risk Rating: 73
- Seasonality Score: 22 (-100 ... +100)
Stock Analysis - Ticker Highlights:
JNJ: JNJ is in an upward trend, with the 10-day moving average crossing above the 50-day moving average on July 21, 2023. This signals a potential buy opportunity, as in 13 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.
Current price $169.99 crossed the support line at $169.60 and is trading between $185.96 resistance and $169.60 support lines. Throughout the month of 06/29/23 - 08/01/23, the price experienced a +3% Uptrend, while the week of 07/25/23 - 08/01/23 shows a -2% Downtrend.
ATXS: ATXS's MACD Histogram just turned positive on July 11, 2023. Looking at past instances where ATXS's MACD turned positive, the stock continued to rise in 38 of 44 cases over the following month. The odds of a continued upward trend are 86%.
Current price $8.95 is below $9.41, the lowest resistance line found by A.I. Throughout the month of 06/29/23 - 08/01/23, the price experienced a +7% Uptrend. During the week of 07/25/23 - 08/01/23, the stock enjoyed a +5% Uptrend growth.
RETA: RETA's Aroon Indicator triggered a bullish signal on August 02, 2023. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. In 191 of 222 similar instances, the stock moved higher in the days that followed. This puts the odds of a move higher at 86%.
Current price $166.51 is above $70.15, the highest support line found by A.I. Throughout the month of 06/29/23 - 08/01/23, the price experienced a +63%
CHRS's RSI Oscillator sits in oversold zone for 4 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
CHRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 10, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on CHRS as a result. In of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for CHRS turned negative on October 16, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHRS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CHRS entered a downward trend on October 21, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (12.657). P/E Ratio (0.000) is within average values for comparable stocks, (111.595). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.971). CHRS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.394) is also within normal values, averaging (225.870).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CHRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a maker of biologic therapeutics for oncology and inflammatory diseases
Industry Biotechnology